載入中
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
前收盤價
US$3.645
+US$0.115 · +3.26%
盤中時間採用ET。市場資料可能有所延遲。
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
日內區間
目前US$3.645
52週區間
目前US$3.645
盤中時間採用ET。市場資料可能有所延遲。
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
日內區間
目前US$3.645
52週區間
目前US$3.645
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1908.8萬 USD | — | — | 1500萬 USD | — |
| 銷貨成本 | 70.5萬 USD | 5.8萬 USD | — | — | 73.4萬 USD |
| 毛利 | 1838.3萬 USD | −5.8萬 USD | — | 1500萬 USD | −73.4萬 USD |
| 研究與開發 | 1867萬 USD | 2980.1萬 USD | 5950.4萬 USD | 2112.5萬 USD | 3793.2萬 USD |
| 銷售、一般及管理費用 | 9085.1萬 USD | 2875.1萬 USD | 1292.5萬 USD | 435.8萬 USD | 2177.7萬 USD |
| 營業費用 | 1.1億 USD | 5855.2萬 USD | 7242.9萬 USD | 2548.3萬 USD | 5970.9萬 USD |
| 利息收入 | 975.6萬 USD | 855.3萬 USD | 218.9萬 USD | — | — |
| 折舊和攤銷 | 28.7萬 USD | 5.8萬 USD | 1.5萬 USD | 8000 USD | 73.4萬 USD |
| 營業利益 | −9113.8萬 USD | −5861萬 USD | −7242.9萬 USD | −1048.3萬 USD | −6044.3萬 USD |
| 淨利 | −8212.7萬 USD | −4976.9萬 USD | −6996.8萬 USD | −1081.1萬 USD | −7076萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.00
上漲空間 92.04%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2024年3月22日 | US$1.03Weekly | 2024年3月18日 | — |
股息 | 2024年3月15日 | US$1.03Weekly | — | — |
除息 2024年3月22日
US$1.03
Weekly
2024年3月18日登記
除息 2024年3月15日
US$1.03
Weekly
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI427.01萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM194.25萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF131.87萬0.00%954億 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM87.27萬0.01%64.1億 USD0.28%US$45.46+0.46%
iShares Biotechnology ETFIBB74.77萬0.01%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO61.52萬0.00%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA41.57萬0.00%218.24億 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT29.95萬0.00%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
